Marcy Graham.

First author, Dr Mary Vail, Monash Department of Biochemistry and Molecular Biology stated: ‘The tumour cells distribute signals to the surrounding area and say: 'We are in need of a blood supply and a foundation upon which to pass on'.’ Related StoriesViralytics enters into medical trial collaboration contract with MSDOvarian cancer patients with a history of oral contraceptive make use of have better outcomesStudy shows rare HER2 missense mutations do not spread breast cancer by themselves’We have proven that EphA3 expressing stromal stem cells, which are produced by the bone marrow, type cells that support and create arteries in tumours,’ Dr Vail stated.The joint venture, officially the Canadian Molecular Imaging Probe Consortium , combines the strengths of both agencies to make a new center of excellence in Toronto to develop and produce molecular imaging probes. These probes are component of an advanced imaging technology that uses medical isotopes to measure the health of patients at a cellular level. Using molecular probes, physicians can diagnose diseases previously and more accurately, monitor the effectiveness of remedies and deliver targeted therapies, often without the need for biopsies or surgeries. CanProbe will establish a new research, production and distribution centre in Toronto which will supply important, often life-saving, molecular probes to support research and scientific imaging applications for UHN-affiliated hospitals and for the global nuclear medicine community.